The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human phase I study of the oral p38 MAPK inhibitor LY2228820 dimesylate in patients with advanced cancer.
Matthew P. Goetz
No relevant relationships to disclose
Anthony W. Tolcher
No relevant relationships to disclose
Paul Haluska
No relevant relationships to disclose
Kyriakos P. Papadopoulos
No relevant relationships to disclose
Charles Erlichman
No relevant relationships to disclose
Muralidhar Beeram
No relevant relationships to disclose
Janet Lensing
No relevant relationships to disclose
Drew Warren Rasco
No relevant relationships to disclose
Julian R. Molina
No relevant relationships to disclose
Rebecca Arcos
No relevant relationships to disclose
Peipei SHI
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Palaniappan Kulanthaivel
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Celine Pitou
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Lynette Mulle
Employment or Leadership Position - PharmaNet/i3
Edward Michael Chan
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Amita Patnaik
No relevant relationships to disclose